Patents Represented by Attorney Todd L. Nath & Associates Juneau
-
Patent number: 6046180Abstract: The present disclosure relates to dipeptidase inhibitors, and more particularly, to novel phosphonate derivatives, hydroxyphosphinyl derivatives, and phosphoramidate derivatives that inhibit N-Acetylated .alpha.-Linked Acidic Dipeptidase (NAALADase) enzyme activity, pharmaceutical compositions comprising such derivatives, and methods of using such derivatives to inhibit NAALADase activity, and to treat prostate diseases, especially using the compounds of the present invention for the inhibition of the growth of prostate cancer cells.Type: GrantFiled: May 27, 1997Date of Patent: April 4, 2000Assignee: Guilford Pharmaceuticals Inc.Inventors: Paul F. Jackson, Barbara S. Slusher, Kevin L. Tays, Keith M. Maclin
-
Patent number: 6025344Abstract: The present disclosure relates to dipeptidase inhibitors, and more particularly, to novel phosphonate derivatives, hydroxyphosphinyl derivatives, and phosphoramidate derivatives that inhibit N-Acetylated .alpha.-Linked Acidic Dipeptidase (NAALADase) enzyme activity, pharmaceutical compositions comprising such derivatives, and methods of using such derivatives to inhibit NAALADase activity, and to treat prostate diseases, especially using the compounds of the present invention for the inhibition of the growth of prostate cancer cells.Type: GrantFiled: May 27, 1997Date of Patent: February 15, 2000Assignee: Guilford Pharmaceuticals Inc.Inventors: Paul F. Jackson, Barbara S. Slusher, Kevin L. Tays, Keith M. Maclin
-
Patent number: 6022878Abstract: This invention relates to the method of using neurotrophic pipecolic acid derivative compounds having an affinity for FKBP-type immunophilins as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity to stimulate or promote neuronal growth or regeneration.Type: GrantFiled: July 10, 1998Date of Patent: February 8, 2000Assignees: GPI NIL Holdings, Inc., John Hopkins University School of MedicineInventors: Joseph P. Steiner, Solomon Snyder, Gregory S. Hamilton, Ted Dawson
-
Patent number: 6011021Abstract: The present disclosure relates to dipeptidase inhibitors, and more particularly, to novel methods of using phosphonate derivatives, hydroxyphosphinyl derivatives, and phosphoramidate derivatives to inhibit N-Acetylated .alpha.-Linked Acidic Dipeptidase (NAALADase) enzyme activity, and to treat prostate diseases, especially using the compounds of the present invention for the inhibition of the growth of prostate cancer cells.Type: GrantFiled: May 28, 1997Date of Patent: January 4, 2000Assignee: Guilford Pharmaceuticals Inc.Inventors: Barbara S. Slusher, Paul F. Jackson, Kevin L. Tays, Keith M. Maclin
-
Patent number: 6004946Abstract: The present invention includes compositions and methods of treatment for glutamate abnormalities and associated nervous tissue insult in a animal by inhibition of NAALADase enzyme. Compositions include glutamate-derived hydroxyphosphinyl derivative compounds, acidic peptide analogs, phosphinic acid derivatives and mixtures thereof that inhibit NAALADase enzyme activity and their use for treating glutamate abnormalities such as created by global and focal ischemia.Type: GrantFiled: July 8, 1997Date of Patent: December 21, 1999Assignee: Guilford Pharmaceuticals Inc.Inventors: Barbara S. Slusher, Paul F. Jackson
-
Patent number: 5981209Abstract: The present invention relates to novel methods and kits for quantitating N-Acetylated .alpha.-Linked Acidic Dipeptidase (NAALADase) enzyme activity in biological samples, including prostate biopsies, seminal fluid, ejaculate, prostatic fluid, blood, saliva, and urine, for the purpose of identifying and differentiating between prostate carcinoma, benign prostatic hyperplasia, and normal prostate.Type: GrantFiled: December 4, 1997Date of Patent: November 9, 1999Assignee: Guilford Pharmaceuticals Inc.Inventors: Barbara S. Slusher, Rena S. Lapidus
-
Patent number: 5935860Abstract: The invention relates to methods for identifying prostatic intraepithelial neoplasia by determining the uteroglobin concentration in a tissue sample.Type: GrantFiled: June 5, 1996Date of Patent: August 10, 1999Assignee: The George Washington UniversityInventors: Steven R. Patierno, Michael J. Manyak
-
Patent number: 5935989Abstract: This invention relates to neurotrophic low molecular weight, small molecule N-linked ureas and carbamates of heterocyclic thioesters having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.Type: GrantFiled: December 31, 1996Date of Patent: August 10, 1999Assignee: GPI NIL Holdings Inc.Inventors: Gregory S. Hamilton, Jia-He Li, Wei Huang
-
Patent number: 5902817Abstract: The present invention relates to thio derivatives that inhibit N-Acetylated .alpha.-Linked Acidic Dipeptidase (NAALADase) enzyme activity, pharmaceutical compositions comprising such derivatives, and methods of using such derivatives to inhibit NAALADase activity, to treat a glutamate abnormality and to treat a prostate disease in an animal.Type: GrantFiled: April 9, 1997Date of Patent: May 11, 1999Assignee: Guilford Pharmaceuticals Inc.Inventors: Paul F. Jackson, Kevin L. Tays, Keith M. Maclin, Barbara S. Slusher
-
Patent number: 5880112Abstract: The present disclosure relates to dipeptidase inhibitors, and more particularly, to N-Acetylated .alpha.-Linked Acidic Dipeptidase (NAALADase) enzyme inhibitors which are proposed as novel agents for the treatment of prostate cancer. NAALADase is enzyme which is a membrane-bound metalloprotease which hydrolyzes the dipeptide, N-acetyl-L-aspartate-L-glutamate (NAAG) to yield glutamate and N-acetylaspartate. The compounds of the present invention include phosphinic acid derivatives that inhibit NAALADase enzyme activity and which have been found useful for inhibiting the growth of prostate cancer cells.Type: GrantFiled: April 8, 1997Date of Patent: March 9, 1999Assignee: Guilford Pharmaceuticals Inc.Inventors: Paul F. Jackson, Barbara S. Slusher
-
Patent number: 5874449Abstract: This invention relates to neurotrophic low molecular weight, small molecule N-linked sulfonamides of heterocyclic thioesters having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.Type: GrantFiled: December 31, 1996Date of Patent: February 23, 1999Assignee: GPI NIL Holdings, Inc.Inventors: Gregory S. Hamilton, Jia-He Li, Wei Huang
-
Patent number: 5863536Abstract: The present invention includes phosphoramidate derivatives, compositions containing the same, and methods of using them as NAALADase inhibitors, particularly for the treatment of glutamate abnormalities and associated nervous tissue insult in a animal and for treatment of prostate disease and prostate cancer by inhibition of NAALADase enzyme.Type: GrantFiled: December 31, 1996Date of Patent: January 26, 1999Assignee: Guilford Pharmaceuticals Inc.Inventors: Paul F. Jackson, Barbara S. Slusher, Kevin L. Tays, Keith M. Maclin
-
Patent number: 5858391Abstract: A bioadherent, orally ingestible system, which comprises: a water-in-oil emulsion system having at least two phases, one phase comprises from about 75% to about 99% by volume of an internal hydrophylic phase and the other phase comprises from about 25% to about 1% by volume of an external hydrophobic phase, wherein the external hydrophobic phase comprises two components, one component being about 3% to about 97% by volume of the hydrophobic phase of a hydrophobic oil and the other being about 97% to about 3% of an emulsifier having a HLB value less than about 10.Type: GrantFiled: May 28, 1997Date of Patent: January 12, 1999Assignee: KV Pharmaceutical CompanyInventors: Robert C. Cuca, Keith S. Lienhop, Thomas Charles Riley, Jr., Mitchell I. Kirschner, R. Saul Levinson
-
Patent number: 5859031Abstract: This invention relates to neurotrophic N-glyoxyl-prolyl ester compounds having an affinity for FKBP-type immunophilins, their preparation and use as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity.Type: GrantFiled: May 21, 1996Date of Patent: January 12, 1999Assignee: GPI NIL Holdings, Inc.Inventors: Gregory S. Hamilton, Joseph P. Steiner
-
Patent number: 5846979Abstract: This invention relates to neurotrophic low molecular weight, small molecule N-oxides of heterocyclic esters, amides, thioesters, and ketones having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.Type: GrantFiled: February 28, 1997Date of Patent: December 8, 1998Assignee: GPI NIL Holdings, Inc.Inventors: Gregory S. Hamilton, Joseph P. Steiner, Eric S. Burak
-
Patent number: 5846981Abstract: This invention relates to the method of using neurotrophic pipecolic acid derivative compounds having an affinity for FKBP-type immunophilins as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity to stimulate or promote neuronal growth or regeneration.Type: GrantFiled: January 23, 1997Date of Patent: December 8, 1998Assignees: GPI NIL Holdings Inc., Johns Hopkins University School of MedicineInventors: Joseph P. Steiner, Solomon Snyder, Gregory S. Hamilton, Ted Dawson
-
Patent number: 5843960Abstract: This invention relates to the method of using neurotrophic pipecolic acid derivative compounds having an affinity for FKBP-type immunophilins as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity to stimulate or promote neuronal growth or regeneration.Type: GrantFiled: January 23, 1997Date of Patent: December 1, 1998Assignees: GPI Nil Holdings, Inc., Johns Hopkins University School of MedicineInventors: Joseph P. Steiner, Solomon Snyder, Gregory S. Hamilton, Ted Dawson
-
Patent number: 5830640Abstract: The invention relates to methods for determining metastatic potential of tumors and to methods and compositions for inhibiting or preventing metastasis of cancers. In one aspect, the invention provides a method to determine metastatic potential of tumors, particularly prostatic tumors. In this regard the invention relates to determining protein or mRNA of effectors of arachadonic acid release to gauge metastatic potential, particularly uteroglobin protein or mRNA to determine metastatic potential of prostatic tumors.The invention also relates to methods and compositions that prevent or inhibit metastasis of cancers. In this regard, the invention particularly relates to methods and compositions that inhibit arachidonic acid, those that inhibit phospholipase A.sub.2. More particularly in this regard, the invention relates to uteroglobin or muteins, peptide analogs or mimetics of uteroglobin and lipocortins or muteins, peptide analogs, or mimetics of lipocortins that inhibit metastasis.Type: GrantFiled: June 7, 1995Date of Patent: November 3, 1998Assignee: George Washington UniversityInventors: Steven R. Patierno, Michael Manyak
-
Patent number: 5824662Abstract: The present invention includes compositions and methods of treatment for glutamate abnormalities and associated nervous tissue insult in a animal by inhibition of NAALADase enzyme. Compositions include glutamate-derived hydroxyphosphinyl derivative compounds, acidic peptide analogs, phosphinic acid derivatives and mixtures thereof that inhibit NAALADase enzyme activity and their use for treating glutamate abnormalities such as created by global and focal ischemia.Type: GrantFiled: September 27, 1996Date of Patent: October 20, 1998Assignee: Guilford Pharmaceuticals Inc.Inventors: Barbara S. Slusher, Paul F. Jackson
-
Patent number: 5804602Abstract: The present invention is based upon the surprising discovery that NAALADase inhibitors exhibit a significant inhibitory effect on the growth of prostate cancer cells. The present disclosure relates to methods of treating diseases of the prostate, in particular prostate cancer, using novel compositions which inhibit N-Acetylated .alpha.-Linked Acidic Dipeptidase (NAALADase) enzyme activity in humans and warm-blooded animals. Furthermore, as NAALADase has been found in other tissues of the body it may serve as a cancer associated protein and thus NAALADase inhibitors would be expected to show efficacy in the treatment of other forms of cancer.Type: GrantFiled: June 17, 1996Date of Patent: September 8, 1998Assignee: Guilford Pharmaceuticals Inc.Inventors: Barbara S. Slusher, Paul F. Jackson